|
[Related PubMed/MEDLINE] Total Number of Papers: 490
|
|
|
[Display Entries]
|
>> all entries
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2020 |
Assessment of Malignancy Potential in Intraductal Papillary Mucinous Neoplasms of the Pancreas on MDCT. |
CI, HRS, ICG, NPV, OR, PPV, WFs |
2 |
2020 |
Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas? |
BD, MD, MN, MN |
3 |
2020 |
Circulating and Salivary Antibodies to Fusobacterium nucleatum Are Associated With Cystic Pancreatic Neoplasm Malignancy. |
ELISA, F. nucleatum, G. adiacens, HGD, S. gordonii |
4 |
2020 |
Comparison of imaging modalities for measuring the diameter of intraductal papillary mucinous neoplasms of the pancreas. |
CT, EUS, LOA, MRI |
5 |
2020 |
Diabetes and Weight Loss Are Associated With Malignancies in Patients With Intraductal Papillary Mucinous Neoplasms. |
OR |
6 |
2020 |
Endosonographic diagnosis of advanced neoplasia in intraductal papillary mucinous neoplasms. |
--- |
7 |
2020 |
Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas. |
PaCa, PDO |
8 |
2020 |
EUS-guided confocal laser endomicroscopy: prediction of dysplasia in intraductal papillary mucinous neoplasms (with video). |
AUC, CI, HGD-Ca, IOA, LGD, nCLE |
9 |
2020 |
Evolution of the immune landscape during progression of pancreatic intraductal papillary mucinous neoplasms to invasive cancer. |
--- |
10 |
2020 |
Genomic characterization of malignant progression in neoplastic pancreatic cysts. |
MCNs |
11 |
2020 |
GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype. |
cfDNA, PCNs |
12 |
2020 |
Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas. |
HGD, HRS, LGD, OR |
13 |
2020 |
Invasive Intraductal Papillary Mucinous Neoplasms: CT Features of Colloid Carcinoma Versus Tubular Adenocarcinoma of the Pancreas. |
MPD |
14 |
2020 |
Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. |
PDAC, SHRs |
15 |
2020 |
Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. |
HGD, MDMs, PDACs |
16 |
2020 |
Methylation changes at the GNAS imprinted locus in pancreatic cystic neoplasms are important for the diagnosis of malignant cysts. |
GNAS, PCF, PDACs |
17 |
2020 |
Mixed-type intraductal papillary mucinous neoplasm: Tailored surgical planning - case report. |
MRCP, MT |
18 |
2020 |
Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. |
--- |
19 |
2020 |
Multilocular Cyst of Type 1 Autoimmune Pancreatitis Masquerading as Cancerization of Intraductal Papillary Mucinous Neoplasm. |
AIP |
20 |
2020 |
Multimodal radiomics and cyst fluid inflammatory markers model to predict preoperative risk in intraductal papillary mucinous neoplasms. |
AUC, CFIM, CT, QI, TANs |
21 |
2020 |
Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy. |
CT, ICG |
22 |
2020 |
Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. |
--- |
23 |
2020 |
Mutational Mosaics of Cell-Free DNA from Pancreatic Cyst Fluids. |
cf, MCNs, PCFs, SCNs |
24 |
2020 |
Noninvasive Discrimination of Low and High-risk Pancreatic Intraductal Papillary Mucinous Neoplasms. |
--- |
25 |
2020 |
Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis. |
GEM, PDAC |
26 |
2020 |
Prognosis of resected intraductal papillary mucinous neoplasm of the pancreas: using revised 2017 international consensus guidelines. |
CI, DSS, HR, RFS |
27 |
2020 |
Psychological distress in patients under surveillance for intraductal papillary mucinous neoplasms of the pancreas: The "Sword of Damocles" effect calls for an integrated medical and psychological approach a prospective analysis. |
Brief-COPE, BSMSS, PSS |
28 |
2020 |
Pylorus-Preserving Total Pancreatectomy for Intraductal Papillary Mucinous Neoplasm in the Setting of Previous Roux-en-Y Cystjejunostomy for Pancreatic Pseudocyst. |
--- |
29 |
2020 |
Recurrent intraductal papillary mucinous neoplasms of the pancreas mimicking ampullary cancer. |
--- |
30 |
2020 |
Role of volumetric multiparametric MRI in distinguishing between intraductal papillary mucinous neoplasms and serous cystadenoma. |
ADC, AUC, PCNs, ROI, SCAs, SI, vADC, vVE |
31 |
2020 |
S6 ribosomal protein phosphorylation is associated with malignancy of intraductal papillary mucinous neoplasm of the pancreas. |
--- |
32 |
2020 |
SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins. |
ADCAs, AMP, CCs, CRC, IHC, SATB2 |
33 |
2020 |
Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas. |
CA19-9, CEA, HGD, INV, S-p53 Ab |
34 |
2020 |
Stratifying Intraductal Papillary Mucinous Neoplasms by Cyst Fluid Analysis: Present and Future. |
--- |
35 |
2020 |
Surgical strategy forintraductal papillary mucinous neoplasms ofthepancreas. |
HGD, IPMC |
36 |
2020 |
Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma. |
IPMN, OS, PanIN, PanINs, PFS |
37 |
2020 |
The Role of Positron Emission Tomography in Clinical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas. |
FDG, ICG, PET, PRISMA |
38 |
2020 |
TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions. |
GEM, IGS, PanIN, TSPO |
39 |
2020 |
Tuft Cells Inhibit Pancreatic Tumorigenesis in Mice by Producing Prostaglandin D2. |
PanIN, PDA |
40 |
2020 |
Validation of Indications for Surgery of European Evidence-Based Guidelines for Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms. |
DM, EEBGPCN, HGD, IC |
41 |
2019 |
A Consensus Study of the Grading and Typing of Intraductal Papillary Mucinous Neoplasms of the Pancreas. |
--- |
42 |
2019 |
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. |
DSS, IPMN |
43 |
2019 |
Age-related morphological changes in the pancreas and their association with pancreatic carcinogenesis. |
PanIN, PDAC |
44 |
2019 |
Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia. |
--- |
45 |
2019 |
Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. |
--- |
46 |
2019 |
Characterization of Intraductal Papillary Neoplasm of the Bile Duct with Respect to the Histopathologic Similarities to Pancreatic Intraductal Papillary Mucinous Neoplasm. |
IPNBs |
47 |
2019 |
Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential. |
--- |
48 |
2019 |
Cyst location and presence of high grade dysplasia or invasive cancer in intraductal papillary mucinous neoplasms of the pancreas: a seven institution study from the central pancreas consortium. |
HGD, HRS, IC, WF |
49 |
2019 |
Cytologic Analysis of Pancreatic Juice Increases Specificity of Detection of Malignant IPMN-A Systematic Review. |
AUC |
50 |
2019 |
Determining Malignant Potential of Intraductal Papillary Mucinous Neoplasm of the Pancreas: CT versus MRI by Using Revised 2017 International Consensus Guidelines. |
IPMN |
51 |
2019 |
Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression. |
--- |
52 |
2019 |
Endoscopic Ultrasound for Early Diagnosis of Pancreatic Cancer. |
CT, EUS, MRI |
53 |
2019 |
Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. |
IL, PCN, PPI |
54 |
2019 |
GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms. |
EGFR |
55 |
2019 |
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. |
BD, EUROPAC, FPC, IQR, PDAC |
56 |
2019 |
Increased Risk of Second Primary Cancers Following Diagnosis of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Population-Based Study. |
CI, HRs, RR, SEER, SIR, SPCs |
57 |
2019 |
Increased SOX9 Expression in Premalignant and Malignant Pancreatic Neoplasms. |
BP, HG, LG |
58 |
2019 |
Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer. |
HGD, LGD, PCNs, SCN |
59 |
2019 |
Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations. |
--- |
60 |
2019 |
Main duct and mixed type intraductal papillary mucinous neoplasms without enhancing mural nodules: Duct diameter of less than 10 mm and segmental dilatation of main pancreatic duct are findings support surveillance rather than immediate surgery. |
CI, HGD, MD, MNs, MPD, OR |
61 |
2019 |
Malignant conversion and peritoneal dissemination after endoscopic ultrasound-guided ethanol ablation in intraductal papillary mucinous neoplasm of the pancreas. |
EUS-PCA |
62 |
2019 |
Management and outcomes of intraductal papillary mucinous neoplasms. |
BD, DSS, MD, MT, PDAC |
63 |
2019 |
MRI Combined with Magnetic Resonance Cholangiopancreatography for Diagnosis of Benign and Malignant Pancreatic Intraductal Papillary Mucinous Neoplasms. |
MRCP, MRI |
64 |
2019 |
Neutrophil to Lymphocyte Ratio is a Predictive Factor of Malignant Potential for Intraductal Papillary Mucinous Neoplasms of the pancreas. |
HGD, IGD, LGD, NLR, PNI |
65 |
2019 |
Neutrophil-to-Lymphocyte Ratio as a Predictor of Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. |
NLR |
66 |
2019 |
Obstructive cholangitis by mucus from an intraductal papillary mucinous neoplasm with pancreatobiliary fistula treated by endoscopic septotomy and direct peroral cholangioscopy: a case report. |
CT, ERCP |
67 |
2019 |
Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. |
PDAs |
68 |
2019 |
Pitfalls of histopathological evaluation of EUS-guided microbiopsies from pancreatic cystic neoplasms. |
SCNs |
69 |
2019 |
Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. |
BD-IPMN |
70 |
2019 |
Prevalence of Asymptomatic Intraductal Papillary Mucinous Neoplasms in Healthy and Ill Populations Detected by Ultrasonography: A Single-Center Study of 6353 Outpatients. |
HRS, OR, WF |
71 |
2019 |
Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. |
--- |
72 |
2019 |
Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. |
--- |
73 |
2019 |
Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. |
HGD-IPMN, LGD-IPMNs, PDAC |
74 |
2019 |
Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry. |
PDAC |
75 |
2019 |
Subtyping of IPMN. |
--- |
76 |
2019 |
Talking Genes in Breast and Pancreatic Malignancies. |
FPC, PDAC |
77 |
2019 |
Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. |
PDAC |
78 |
2019 |
The Clinical Management of Main Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas. |
MPD |
79 |
2019 |
Usefulness of Deep Learning Analysis for the Diagnosis of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. |
AI, EUS |
80 |
2019 |
What is the Outcome of Patients Affected by Intraductal Papillary Mucinous Neoplasms Without High-Risk Stigmata?: A Single-Center Retrospective Study. |
HRS |
81 |
2018 |
A case of intraductal papillary-mucinous neoplasm of the pancreas penetrating into the stomach and spleen successfully treated by total pancreatectomy. |
CT, IPMC |
82 |
2018 |
A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. |
PDAC |
83 |
2018 |
Are pancreatic IPMN volumes measured on MRI images more reproducible than diameters? An assessment in a large single-institution cohort. |
ICCs, LOA |
84 |
2018 |
ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma inMice. |
ATP, PanINs, PDACs, PDCs |
85 |
2018 |
Cells of origin of pancreatic neoplasms. |
MCNs, PanINs, PDAC |
86 |
2018 |
Clinical and Radiographic Gastrointestinal Abnormalities in McCune-Albright Syndrome. |
GI, MAS, MRCP |
87 |
2018 |
Conditional survival analysis for patients with intraductal papillary mucinous neoplasms (IPMNs) undergoing curative resection. |
CS, MD, PD, SEER, UD, WD |
88 |
2018 |
CT radiomics to predict high-risk intraductal papillary mucinous neoplasms of the pancreas. |
AUC, BD |
89 |
2018 |
Curative resection of pancreatic ductal adenocarcinoma developing in the remnant pancreas 13 years after distal pancreatectomy for intraductal papillary mucinous neoplasms: A case report. |
PDAC |
90 |
2018 |
Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. |
MCNs |
91 |
2018 |
Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. |
BD |
92 |
2018 |
Does Surgical Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms?: A Multi-institutional Study. |
--- |
93 |
2018 |
Evaluation of the International Consensus Guidelines for the Surgical Resection of Intraductal Papillary Mucinous Neoplasms. |
MPD |
94 |
2018 |
GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling. |
PDACs, YAP |
95 |
2018 |
Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. |
HGD, IHC, LGD |
96 |
2018 |
Imaging Follow-up of Low-Risk Incidental Pancreas and Kidney Findings: Effects of Patient Age and Comorbidity on Projected Life Expectancy. |
LE, SB |
97 |
2018 |
Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. |
CECs |
98 |
2018 |
Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. |
--- |
99 |
2018 |
Intraductal papillary mucinous neoplasms of the pancreas: a clinical challenge. |
--- |
100 |
2018 |
Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk. |
--- |
|